Interpace Biosciences Reports 22% Revenue Drop, 56% Net Income Decline Amid Massive Dilution
IDXG has more than doubled off its 52-week low of $0.443.
Summary
Interpace Biosciences reported a significant 22% year-over-year revenue decrease and a 56% net income decline for Q1 2026, primarily due to the discontinuation of its PancraGEN test and substantial dilution from a preferred stock conversion.
Key Events · Earnings and Guidance · IDXG
-
Revenue Decline
Net revenue decreased by 22% year-over-year to $9.0 million for Q1 2026, compared to $11.5 million in Q1 2025, primarily due to the discontinuation of the PancraGEN test.
-
Profitability Drop
Net income fell by 56% to $0.7 million for Q1 2026, and diluted EPS decreased by 50% to $0.03 per share, compared to $1.6 million and $0.06 respectively in Q1 2025.
-
Massive Dilution from Preferred Stock Conversion
All Series C Preferred Stock converted into approximately 23.3 million common shares in January 2026, increasing outstanding shares from 4.4 million to 27.7 million, a dilution of over 500%.
-
Debt Elimination
The company eliminated its note payable interest for Q1 2026, indicating the repayment of its former Term Loan.
Analysis · IDXG · Industrial Applications And Services
This quarterly report reveals a challenging financial period for Interpace Biosciences, marked by a substantial decline in revenue and net income. The primary driver for the revenue drop was the discontinuation of the PancraGEN test, a previously known issue. The most significant market-moving event is the massive dilution from the conversion of Series C Preferred Stock into 23.3 million common shares, which dramatically increased the outstanding share count and significantly impacted per-share metrics. While the company successfully eliminated its debt and projects sufficient liquidity for the near term, the severe dilution and ongoing revenue pressures present a negative outlook for existing shareholders. The company continues to pursue an uplisting to Nasdaq, which could improve capital-raising capabilities if successful.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDXG was trading at $2.00 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $55.4M. The 52-week trading range was $0.44 to $2.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.